• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大肠杆菌DNA促旋酶A中的一种新型双突变赋予对喹诺酮类抗生素的抗性。

A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics.

作者信息

Truong Q C, Nguyen Van J C, Shlaes D, Gutmann L, Moreau N J

机构信息

Laboratoire de Recherche Moléculaire sur les Antibiotiques, Université Paris VI, France.

出版信息

Antimicrob Agents Chemother. 1997 Jan;41(1):85-90. doi: 10.1128/AAC.41.1.85.

DOI:10.1128/AAC.41.1.85
PMID:8980760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163665/
Abstract

A spontaneous Escherichia coli mutant, named Q3, resistant to nalidixic acid was obtained from a previously described clinical isolate of E. coli, Q2, resistant to fluoroquinolones but susceptible to nalidixic acid (E. Cambau, F. Bordon, E. Collatz, and L. Gutmann, Antimicrob. Agents Chemother. 37:1247-1252, 1993). Q3 harbored the mutation Asp82Gly in addition to the Gly81Asp mutation of Q2. The different mutations leading to Gly81Asp, Asp82Gly, and Gly81AspAsp82Gly were introduced into the gyrA gene harbored on plasmid pJSW102, and the resulting plasmids were introduced into E. coli KNK453 (gyrAts) by transformation. The presence of Asp82Gly or Gly81Asp alone led to a low-level resistance to fluoroquinolones but not to nalidixic acid resistance. When both mutations were present, resistance to both nalidixic acid and fluoroquinolones was expressed. Purified gyrases of the different mutants showed similar rates of supercoiling. Dominance of the various gyrA mutant alleles harbored on plasmids was examined. The susceptibility to quinolones associated with wild-type gyrA was always dominant. The susceptibility to nalidixic acid expressed by the Gly81Asp mutant was dominant, while that expressed by the Asp82Gly mutant was recessive. From these results, we hypothesize that some amino acids within the quinolone resistance-determining region of gyrase A are more important for the association of subunits rather than for the activity of the holoenzyme.

摘要

从先前描述的一株对氟喹诺酮耐药但对萘啶酸敏感的大肠杆菌临床分离株Q2中获得了一株自发的对萘啶酸耐药的大肠杆菌突变体,命名为Q3(E. 坎博、F. 博尔东、E. 科拉茨和L. 古特曼,《抗菌剂与化疗》37:1247 - 1252,1993年)。除了Q2的Gly81Asp突变外,Q3还存在Asp82Gly突变。导致Gly81Asp、Asp82Gly和Gly81AspAsp82Gly的不同突变被引入质粒pJSW102携带的gyrA基因中,所得质粒通过转化导入大肠杆菌KNK453(gyrAts)。单独存在Asp82Gly或Gly81Asp会导致对氟喹诺酮的低水平耐药,但不会导致对萘啶酸耐药。当两种突变都存在时,则表现出对萘啶酸和氟喹诺酮的耐药性。不同突变体的纯化回旋酶显示出相似的超螺旋速率。研究了质粒携带的各种gyrA突变等位基因的显性情况。与野生型gyrA相关的对喹诺酮的敏感性总是占主导地位。Gly81Asp突变体所表现出的对萘啶酸的敏感性是显性的,而Asp82Gly突变体所表现出的敏感性是隐性的。根据这些结果,我们推测回旋酶A的喹诺酮耐药决定区域内的某些氨基酸对于亚基的结合比对全酶的活性更为重要。

相似文献

1
A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics.大肠杆菌DNA促旋酶A中的一种新型双突变赋予对喹诺酮类抗生素的抗性。
Antimicrob Agents Chemother. 1997 Jan;41(1):85-90. doi: 10.1128/AAC.41.1.85.
2
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.一株对氟喹诺酮类耐药但对萘啶酸不耐药的大肠杆菌中的新型gyrA点突变。
Antimicrob Agents Chemother. 1993 Jun;37(6):1247-52. doi: 10.1128/AAC.37.6.1247.
3
Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.环丙沙星与氟喹诺酮类药物。作用机制与耐药性的新概念
Am J Med. 1989 Nov 30;87(5A):2S-8S. doi: 10.1016/0002-9343(89)90010-7.
4
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
5
Quinolone action in Escherichia coli cells carrying gyrA and gyrB mutations.携带gyrA和gyrB突变的大肠杆菌细胞中的喹诺酮作用。
FEMS Microbiol Lett. 1993 Jan 15;106(2):187-91. doi: 10.1016/0378-1097(93)90079-h.
6
New Escherichia coli gyrA and gyrB mutations which have a graded effect on DNA supercoiling.对DNA超螺旋具有分级效应的新型大肠杆菌gyrA和gyrB突变
Mol Gen Genet. 1989 Oct;219(1-2):306-12. doi: 10.1007/BF00261192.
7
Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.由于gyrA基因突变导致粘质沙雷氏菌自发喹诺酮耐药。
Antimicrob Agents Chemother. 1991 May;35(5):898-902. doi: 10.1128/AAC.35.5.898.
8
Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.铜绿假单胞菌耐环丙沙星菌株中的II型拓扑异构酶突变
Antimicrob Agents Chemother. 1999 Jan;43(1):62-6. doi: 10.1128/AAC.43.1.62.
9
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.体外筛选的大肠杆菌氟喹诺酮耐药突变体的特性分析
Antimicrob Agents Chemother. 1994 Jun;38(6):1284-91. doi: 10.1128/AAC.38.6.1284.
10
A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.鼠伤寒沙门氏菌耐氟喹诺酮临床分离株中的一种新型gyrB突变。
FEMS Microbiol Lett. 1995 Oct 1;132(1-2):57-60. doi: 10.1111/j.1574-6968.1995.tb07810.x.

引用本文的文献

1
Genome-Scale Metabolic Models and Machine Learning Reveal Genetic Determinants of Antibiotic Resistance in Escherichia coli and Unravel the Underlying Metabolic Adaptation Mechanisms.基因组规模代谢模型与机器学习揭示大肠杆菌抗生素耐药性的遗传决定因素并阐明潜在的代谢适应机制。
mSystems. 2021 Aug 31;6(4):e0091320. doi: 10.1128/mSystems.00913-20. Epub 2021 Aug 3.
2
Changes in the Carbon Metabolism of During the Evolution of Doxycycline Resistance.多西环素耐药性进化过程中碳代谢的变化
Front Microbiol. 2019 Nov 1;10:2506. doi: 10.3389/fmicb.2019.02506. eCollection 2019.
3
Transferable Mechanisms of Quinolone Resistance from 1998 Onward.1998 年以来喹诺酮类耐药的可转移机制。
Clin Microbiol Rev. 2019 Aug 14;32(4). doi: 10.1128/CMR.00007-19. Print 2019 Sep 18.
4
Carrion's Disease: the Sound of Silence.卡利翁病:无声的喧嚣。
Clin Microbiol Rev. 2017 Nov 29;31(1). doi: 10.1128/CMR.00056-17. Print 2018 Jan.
5
Fluoroquinolone resistance mechanisms of Shigella flexneri isolated in Bangladesh.孟加拉国分离的福氏志贺菌对氟喹诺酮的耐药机制
PLoS One. 2014 Jul 16;9(7):e102533. doi: 10.1371/journal.pone.0102533. eCollection 2014.
6
Selective alleviation of Mitomycin C sensitivity in lexA3 strains of Escherichia coli demands allele specificity of rif-nal mutations: a pivotal role for rpoB87-gyrA87 mutations.筛选出的对丝裂霉素 C 敏感性降低的大肠杆菌 lexA3 菌株需要 rif-nal 突变的等位基因特异性:rpoB87-gyrA87 突变起关键作用。
PLoS One. 2014 Feb 3;9(2):e87702. doi: 10.1371/journal.pone.0087702. eCollection 2014.
7
Resistance to Fluoroquinolone by a Combination of Efflux and Target Site Mutations in Enteroaggregative Escherichia coli Isolated in Korea.韩国分离出的肠聚集性大肠杆菌中通过外排和靶点突变联合作用对氟喹诺酮产生耐药性
Osong Public Health Res Perspect. 2012 Dec;3(4):239-44. doi: 10.1016/j.phrp.2012.11.002.
8
Global fluoroquinolone resistance epidemiology and implictions for clinical use.全球氟喹诺酮类药物耐药性流行病学及其临床应用意义
Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14.
9
Growth and Survival of Acid-Resistant and Non-Acid-Resistant Shiga-Toxin-Producing Escherichia coli Strains during the Manufacture and Ripening of Camembert Cheese.在卡门培尔奶酪的制作和成熟过程中,产志贺毒素大肠杆菌耐酸和非耐酸菌株的生长与存活情况
Int J Microbiol. 2009;2009:653481. doi: 10.1155/2009/653481. Epub 2009 Feb 11.
10
Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.新型非氟喹诺酮类细菌II型拓扑异构酶抑制剂抗生素NXL101的作用机制
Antimicrob Agents Chemother. 2008 Sep;52(9):3339-49. doi: 10.1128/AAC.00496-08. Epub 2008 Jul 14.

本文引用的文献

1
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.大肠杆菌DNA拓扑异构酶IV parC基因的喹诺酮抗性突变体
Antimicrob Agents Chemother. 1996 Mar;40(3):710-14. doi: 10.1128/AAC.40.3.710.
2
Structure and mechanism of DNA topoisomerase II.DNA拓扑异构酶II的结构与机制。
Nature. 1996 Jan 18;379(6562):225-32. doi: 10.1038/379225a0.
3
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.一株对氟喹诺酮类耐药但对萘啶酸不耐药的大肠杆菌中的新型gyrA点突变。
Antimicrob Agents Chemother. 1993 Jun;37(6):1247-52. doi: 10.1128/AAC.37.6.1247.
4
Mechanism of action of quinolones against Escherichia coli DNA gyrase.喹诺酮类药物对大肠杆菌DNA旋转酶的作用机制。
Antimicrob Agents Chemother. 1993 Apr;37(4):839-45. doi: 10.1128/AAC.37.4.839.
5
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.一株高度耐氟喹诺酮的大肠杆菌临床分离株gyrA基因中的突变。
Antimicrob Agents Chemother. 1993 Apr;37(4):696-701. doi: 10.1128/AAC.37.4.696.
6
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex.DNA 回旋酶 A 蛋白中的单个点突变极大地降低了氟喹诺酮类药物与回旋酶-DNA 复合物的结合。
Antimicrob Agents Chemother. 1993 Jan;37(1):126-7. doi: 10.1128/AAC.37.1.126.
7
Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.临床分离株中喹诺酮耐药机制:司帕沙星及不同疏水性氟喹诺酮类药物的蓄积,以及膜成分分析。
J Antimicrob Chemother. 1993 Sep;32(3):379-92. doi: 10.1093/jac/32.3.379.
8
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus.由于gyrase A蛋白变化和条件性喹诺酮抗性位点鉴定导致的质粒互补试验在确定喹诺酮抗性方面的局限性。
Antimicrob Agents Chemother. 1993 Dec;37(12):2588-92. doi: 10.1128/AAC.37.12.2588.
9
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.体外筛选的大肠杆菌氟喹诺酮耐药突变体的特性分析
Antimicrob Agents Chemother. 1994 Jun;38(6):1284-91. doi: 10.1128/AAC.38.6.1284.
10
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.耐环丙沙星的大肠埃希菌临床分离株gyrA基因双突变与最低抑菌浓度之间的关联
Antimicrob Agents Chemother. 1994 Oct;38(10):2477-9. doi: 10.1128/AAC.38.10.2477.